Restenosis following coronary angioplasty: Clinical presentations and therapeutic options

Clinical Cardiology

Volumn 18, Issue 12, 1995, Pages 693-703

  Levine, Glenn N ^a   Chodos, Andrew P ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

percutaneous transluminal coronary angioplasty; recurrent restenosis; restenosis

Indexed keywords

ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; ECHOGRAPHY; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; REOPERATION; RESTENOSIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; HUMANS; RECURRENCE;

EID: 0029559473     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.4960181203     Document Type: Review

References (81)

1. Symposium on restenosis: From basic studies to clinical trials. Introduction
2. Does the new angiotensin‐converting enzyme inhibitor cilazapril prevent restenosis after percutaneous coronary angioplasty?
3. Relation between myocardial blood flow and the severity of coronary artery stenosis
4. Coronary flow reserve as a physiologic measure of stenosis severity
5. Does visual interpretation of the coronary arteriogram predict the physiologic importance of a coronary stenosis?
6. Defining coronary restenosis: Newer clinical and angiographic paradigms
7. Histologic findings in specimens obtained by percutaneous directional coronary atherectomy
8. Analysis of atherectomy specimens
9. Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients
10. Restenosis after percutaneous transluminal coronary angioplasty—a histopathological study using autopsied hearts
11. Percutaneous coronary angioscopy with restenosis after coronary angioplasty
12. Restenosis after percutaneous coronary transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung, and Blood Institute
13. Restenosis after percutaneous transluminal coronary angioplasty
14. Restenosis after successful percutaneous transluminal coronary angioplasty: The Montreal Heart Institute experience
15. Restenosis after percutaneous transluminal coronary angioplasty: The Emory University Hospital experience
16. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial follow‐up of 229 patients
17. Coronary angioplasty: Clinical and angiographic follow‐up
18. Restenosis and repeat coronary angioplasty in Geneva
19. Recurrent restenosis after transluminal coronary angioplasty—dilatation or surgery?
20. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease
21. Restenosis: The clinical issues
22. Restenosis after coronary angioplasty: An overview
23. Restenosis following coronary angioplasty: Patterns, recognition, and results of repeat angioplasty
24. Incidence of restenosis after successful coronary angioplasty: A time‐related phenomenon
25. Aggressive clinical pattern of angina at restenosis following coronary angioplasty
26. Initial presentation predicts clinical manifestations of restenosis after successful coronary angioplasty
27. Clinical characteristics and angiographic follow‐up of patients undergoing early or late repeat dilatation for a first restenosis
28. Can restenosis after coronary angioplasty be predicted from clinical variables?
29. Restenosis after coronary angioplasty: An overview
30. Patient, lesion, and procedural variables as risk factors for luminal re‐narrowing after successful coronary angioplasty: A quantitative analysis of 653 patients with 778 lesions
31. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test
32. Efficacy of repeat percutaneous transluminal coronary angioplasty for coronary restenosis
33. Angiographic findings when chest pain recurs after successful percutaneous transluminal coronary angioplasty
34. Intracoronary ultrasound predictors of adverse outcomes after coronary artery interventions
35. Exercise echocardiography is a valuable adjunct to treadmill testing for detection of restenosis after coronary angioplasty
36. Stress thallium‐201 imaging after coronary angioplasty predicts restenosis and recurrent symptoms
37. Usefulness of dobutamine echocardiography for detecting restenosis after percutaneous transluminal coronary angioplasty
38. The management of patients following successful coronary angioplasty
39. Repeat coronary angioplasty
40. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis
41. Repeat coronary angioplasty for restenosis: Results and predictors of follow‐up clinical events
42. Repeat coronary angioplasty: Correlates of a second restenosis
43. Outcome in patients with recurrent restenosis after percutaneous transluminal balloon angioplasty
44. Repeat coronary angioplasty as treatment for restenosis
45. Repeat coronary angioplasty: Efficacy of a third angioplasty for a second restenosis
46. Results of directional atherectomy of primary atheromatous and restenosis lesions in coronary arteries and saphenous vein grafts
47. Analysis of late lumen narrowing after excimer laser‐facilitated coronary angioplasty
48. Percutaneous excimer coronary angioplasty: Results in the first consecutive 3,000 patients
49. Wiktor stent implantation in patients with restenosis following balloon angioplasty of a native coronary artery
50. Major clinical events after coronary stenting
51. A comparison of balloon‐expandable‐stent implantation with balloon angioplasty in patients with coronary artery disease
52. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease
53. Caveats about elective coronary stenting
54. Initial management and long‐term clinical outcome of restenosis after initially successful percutaneous transluminal coronary angioplasty
55. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty
56. Long‐term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty
57. Low molecular weight heparin in prevention of restenosis after angioplasty: Results of enoxaparin restenosis (ERA) trial
58. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: A randomized trial
59. Pharmacologic prevention of restenosis after coronary angioplasty: Review of the randomized clinical trials
60. The impact of fish oil on restenosis following coronary angioplasty: The fish oil restenosis trial (FORT)
61. A meta‐analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty
62. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
63. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
64. The basis of molecular stategies for treating coronary restenosis after angioplasty
65. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery
66. Verapamil treatment and coronary angioplasty in patients at high risk of restenosis
67. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty
68. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
69. Randomized trial of fish oil for prevention of restenosis after coronary angioplasty
70. A prospective, randomized, and double‐blind trial on the effect of fish oil on the incidence of restenosis following PTCA
71. Double‐blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty
72. Effects of low‐dose aspirin on restenosis after coronary angioplasty
73. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
74. Effect of short‐term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty
75. Effects of diltiazem on complications and restenosis after coronary angioplasty
76. Effect of 18‐to 24‐hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
77. Recognition of restenosis: Can patients be defined in whom the exercise‐ECG result makes angiographic restudy unnecessary?
78. Immediate and 6‐month follow‐up results of coronary angioplasty for restenosis: Analysis of factors predicting recurrent clinical restenosis
79. Initial and late outcome after a third coronary angioplasty (PTCA) for recurrent native coronary restenosis
80. Percutaneous transluminal coronary angioplasty more than twice for the same coronary lesion
81. Treatment of recurrent restenosis with repeat percutaneous transluminal coronary angioplasty